See previous posts by people here on p21. It is not a simple biomarker. It's MOA is very poorly understood and it can in some cases be a contra-indication of anti-tumor activity. It has to be evaluated scientifically using conditional statistics, and will still not be conclusive. Kevetrin's efficacy will be proven on tumor and lesion progression, patient survival, QoL, etc, not p21. Seeing p21 increase simply means Kevetrin is "working" in a molecular sense. (Which is good; it can't be therapeutic without "working". But it can "work" and not be therapeutic. I hope people understand that.)
Patience.
News 
Market Data 
Discover 
